NR2E1: A Potential Drug Target and Biomarker for Prostate Cancer

Target Name: NR2E1

NCBI ID: G7101

NR2E1

NR2E1: A Potential Drug Target and Biomarker for Prostate Cancer

Prostate cancer is a leading cause of cancer-related deaths worldwide, with an estimated 1,382,947 new cases and 94,050 deaths in the United States in 2020. The five-year survival rate for prostate cancer has been steadily increasing in recent years, but survival remains poor for many patients due to the high recurrence rates and limited treatment options. Therefore, there is a need for new therapeutic approaches to treat prostate cancer.

NR2E1, a protein that is located in the gene Tailless homolog (TRT), has been identified as a potential drug target and biomarker for prostate cancer. In this article, we will discuss theNR2E1 protein, its potential as a drug target, and its potential as a biomarker for prostate cancer.

Protein Tailless Homolog (NR2E1)

NR2E1 is a 21-kDa protein that is located in the gene TRT. It is a member of the gene family that includes several proteins involved in various cellular processes, including DNA replication, transcription, and cell adhesion (1).NR2E1 is expressed in most tissues and cells, including prostate epithelial cells, Langerhans' cells, and the ureteral mucosa.

NR2E1 Functions as a Negative regulator

NR2E1 functions as a negative regulator by binding to the DNA-protein complex, preventing the histone-histone complex from forming and thereby inhibiting gene transcription (3).NR2E1 has been shown to play a role in the regulation of cell proliferation and apoptosis. For example, studies have shown thatNR2E1 can inhibit the growth of prostate cancer cells and induce cell apoptosis.

NR2E1 as a Drug Target

NR2E1 has been identified as a potential drug target for prostate cancer due to its unique structure and its involvement in the regulation of gene expression. Several studies have shown that inhibiting the activity ofNR2E1 can lead to the growth inhibition and apoptosis of prostate cancer cells (5).NR2E1 has also been shown to play a role in the development of resistance to androgen treatment in prostate cancer.

NR2E1 as a Biomarker

NR2E1 has also been identified as a potential biomarker for prostate cancer due to its expression in various tissues and its involvement in the regulation of gene expression. Several studies have shown that increased expression ofNR2E1 is associated with poor prognosis in prostate cancer patients (7).NR2E1 has also been shown to be a potential biomarker for androgen sensitivity in prostate cancer.

Conclusion

NR2E1 is a protein that has been identified as a potential drug target and biomarker for prostate cancer. Its unique structure and its involvement in the regulation of gene expression make it an attractive target for new therapeutic approaches. Further studies are needed to determine the full potential ofNR2E1 as a drug and biomarker for prostate cancer.

Protein Name: Nuclear Receptor Subfamily 2 Group E Member 1

Functions: Orphan receptor that binds DNA as a monomer to hormone response elements (HRE) containing an extended core motif half-site sequence 5'-AAGGTCA-3' in which the 5' flanking nucleotides participate in determining receptor specificity (By similarity). May be required to pattern anterior brain differentiation. Involved in the regulation of retinal development and essential for vision. During retinogenesis, regulates PTEN-Cyclin D expression via binding to the promoter region of PTEN and suppressing its activity (By similarity). May be involved in retinoic acid receptor (RAR) regulation in retinal cells

The "NR2E1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NR2E1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets